Redhill Biopharma company info

What does Redhill Biopharma do?
Redhill Biopharma (TASE:RDHL), (NASDAQ:RDHL) is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of a variety of diseases, including gastrointestinal and inflammatory disorders and cancer. With a deep commitment to innovation, Redhill conducts research and clinical development programs to bring new therapies to market that aim to improve patient outcomes. The company's portfolio spans both early and late-stage projects, targeting unmet medical needs with the potential to offer better efficacy or safety profiles than existing treatments. Redhill's objectives are centered on advancing its pipeline through clinical trials, securing partnerships for broader global reach, and ultimately transforming promising scientific discoveries into accessible medical solutions for patients worldwide.
Redhill Biopharma company media
Company Snapshot

Is Redhill Biopharma a public or private company?

key
Ownership
Public

How many people does Redhill Biopharma employ?

people
Employees
53

What sector is Redhill Biopharma in?

pie chart
Sector
Health Care

Where is the head office for Redhill Biopharma?

location pin
Head Office
Tel Aviv, Israel

What year was Redhill Biopharma founded?

founded flag
Year Founded
2009
What does Redhill Biopharma specialise in?
/Gastrointestinal Therapies /Oncology Treatments /Inflammatory Disease Medications /Clinical Research /Drug Development /Biopharmaceutical Innovations

What are the products and/or services of Redhill Biopharma?

Overview of Redhill Biopharma offerings
Talicia - a treatment for Helicobacter pylori infection designed to reduce antibiotic resistance.
Movantik - an oral solution for opioid-induced constipation in adult patients with chronic non-cancer pain.
Opaganib - an orally-administered, sphingosine kinase-2 inhibitor being tested for multiple indications including COVID-19 and cancer.
RHB-204 - an oral antibiotic combination therapy for the treatment of nontuberculous mycobacterial (NTM) infections.
RHB-107 - an oral serine protease inhibitor targeting cancer, inflammatory disease, and COVID-19-related symptoms in outpatient settings.
RHB-104 - a combination antibiotic therapy aimed at treating Crohn's disease with a suspected mycobacterial infection etiology.

Who is in the executive team of Redhill Biopharma?

Redhill Biopharma leadership team
  • Mr. Dror  Ben-Asher
    Mr. Dror Ben-Asher
    Co-Founder, Chairman & CEO
  • Mr. Razi  Ingber
    Mr. Razi Ingber
    Chief Financial Officer
  • Mr. Gilead  Raday MPhil, MSc
    Mr. Gilead Raday MPhil, MSc
    Chief Operating Officer
  • Mr. Adi  Frish
    Mr. Adi Frish
    Chief Corporate & Business Development Officer
  • Mr. Rick D. Scruggs
    Mr. Rick D. Scruggs
    Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
  • Ms. Alexandra  Okmian
    Ms. Alexandra Okmian
    Senior Business Development & Investor Relations Manager
  • Dr. Reza  Fathi Ph.D.
    Dr. Reza Fathi Ph.D.
    Senior Vice President of Research & Development
  • Mr. Guy  Goldberg J.D.
    Mr. Guy Goldberg J.D.
    Chief Business Officer